Kennametal stock jumps on Jefferies upgrade as tungsten prices hit fresh highs
13 January 2026
1 min read

Kennametal stock jumps on Jefferies upgrade as tungsten prices hit fresh highs

New York, January 13, 2026, 12:28 EST — Regular session

  • Kennametal (KMT) shares climb following Jefferies’ upgraded outlook on the toolmaker
  • Tungsten prices surge, dragging raw-material costs back into the spotlight for industrial firms
  • Investors are eyeing the upcoming earnings report for clues on margins and demand

Kennametal Inc shares jumped about 8.4% to $33.32 in midday trading Tuesday after Jefferies upgraded the industrial toolmaker and raised its price target. The stock gained $2.60, hitting a high of $34.14, with volume just over 1 million shares. (TradingView)

The timing is tricky for investors: tungsten, crucial for carbide cutting tools, has been surging. On Tuesday, a China benchmark for ammonium paratungstate (APT)—a key intermediate for pricing tungsten—hit 725,000 yuan per metric ton, according to Shanghai Metal Market data. (Metal)

Jefferies analyst Stephen Volkmann upgraded Kennametal from Hold to Buy, boosting his price target from $28 to $40. The catalyst? An “unprecedented price spike” in tungsten. According to Jefferies, this surge should boost near-term earnings since price hikes tend to hit the top line before input costs catch up. The firm also highlighted that short-cycle markets, the quicker-moving segments of manufacturing, are showing early signs of a rebound—making now a good moment to hold. (TipRanks)

Other analysts have adjusted their targets too. UBS’s Steven Fisher maintained a Neutral rating—basically a hold—but raised his price target to $32 from $28 in a Monday note. (GuruFocus)

Morgan Stanley’s Angel Castillo stuck with an Equal-Weight rating—essentially a hold—and bumped up his price target to $29 from $27. The stock’s jump on Tuesday pushed it past both marks. (GuruFocus)

Kennametal, the Pittsburgh-based maker of metal-cutting tools and wear-resistant parts for aerospace, transportation, and energy sectors, competes with companies like Sandvik. In November’s quarterly report, the company raised its annual guidance, projecting second-quarter sales between $500 million and $520 million, with adjusted earnings per share in the range of $0.30 to $0.40; these “adjusted” figures exclude items such as restructuring costs. CEO Sanjay Chowbey described the quarter as having “started off strong.” (Kennametal)

Tungsten has rattled some industries since last year, following price surges fueled by U.S.-China trade tensions and Beijing’s export restrictions on key metals, Reuters noted in October. That uncertainty has investors skittish about how fast manufacturers can pass on higher costs. (Reuters)

Timing cuts both ways. Kennametal flagged in regulatory filings that shifts in raw material availability and commodity prices can cause swings in results. A sudden drop in tungsten prices could squeeze margins as fast as a rise could boost them.

The next major event is the company’s earnings report due Feb. 4. Investors will be watching closely for any guidance changes and updates on how pricing is tracking against input costs. Zacks forecasts earnings around $0.33 per share for this release. (Zacks)

Stock Market Today

  • ABBV inks drug pricing deal with Trump, joins PD-1xVEGF bandwagon
    January 13, 2026, 2:32 PM EST. AbbVie said it signed a U.S. pricing agreement with the Trump administration to cut list prices to match those in comparable developed markets, backing the MFN proposal. The deal includes a three-year exemption from import tariffs on pharmaceutical ingredients if AbbVie expands U.S. manufacturing, and a pledge to invest $100 billion over the next decade in domestic R&D and capital. The government says 16 of 17 large drugmakers have reached similar accords; Regeneron remains in talks. In a separate release, AbbVie agreed to an exclusive license with RemeGen for its PD-1xVEGF bispecific, RC148. AbbVie will pay an upfront $650 million and up to $4.95 billion in milestones, plus royalties, for rights outside Greater China. RC148 is in phase II in China, with potential in NSCLC and CRC. Competitors include Summit, BioNTech/Bristol Myers, Merck and Pfizer pursuing PD-1/VEGF programs.
Why Goldman Sachs stock is down today: Apple Card handoff and CPI sharpen focus on Jan. 15 earnings
Previous Story

Why Goldman Sachs stock is down today: Apple Card handoff and CPI sharpen focus on Jan. 15 earnings

Thermo Fisher stock slides as Nvidia AI lab deal meets COO exit and March reshuffle
Next Story

Thermo Fisher stock slides as Nvidia AI lab deal meets COO exit and March reshuffle

Go toTop